NCT04445714View on ClinicalTrials.gov

To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

March 14, 2023

Study Completion Date

March 14, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

dapagliflozin and saxagliptin

Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally

Trial Locations (9)

110076

Research Site, New Delhi

160012

Research Site, Chandigarh

160062

Research Site, Mohali

226003

Research Site, Lucknow

500024

Research Site, Hyderabad

560017

Research Site, Bangalore

641018

Research Site, Coimbatore

700020

Research Site, Kolkata

751007

Research Site, Bhubaneswar

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY